• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BioCardia

BioCardia wins CE Mark renewal for Helix, Morph catheters

October 9, 2019 By Sean Whooley

BioCardia

BioCardia (OTC:BCDA) said yesterday that it won CE Mark renewal for its Helix biotherapeutic delivery catheter and Morph universal deflectable guide catheter for delivery of biotherapeutics to the heart. With the renewed CE Mark, BioCardia said it can continue supporting partners outside the U.S. and move forward with commercial sales of the Helix and Morph systems […]

Filed Under: Cardiovascular, Featured, Regenerative Medicine, Regulatory/Compliance Tagged With: BioCardia

BioCardia touts preliminary data from heart failure trial

August 23, 2018 By Sarah Faulkner

BioCardia

BioCardia (OTC:BCDA) touted data today from the first 10 patients treated in its Phase III CardiAmp heart failure trial. The company’s investigational therapy uses a patient’s bone marrow cells to trigger the body’s natural ability to heal itself, according to BioCardia. These data are the first to be published from any pivotal trial of a stem […]

Filed Under: Cardiovascular, Clinical Trials, Featured, Wall Street Beat Tagged With: BioCardia

BioCardia wins FDA nod for chronic myocardial ischemia pivotal trial

January 30, 2018 By Sarah Faulkner

BioCardia

The FDA has approved a trial to test BioCardia‘s (OTC:BCDA) CardiAMP cell therapy in chronic myocardial ischemia patients with refractory angina. The San Carlos, Calif.-based company could enroll up to 343 patients in the pivotal trial, which is designed to support benefit claims for the cell therapy product without the need for a second confirmatory […]

Filed Under: Cardiovascular, Featured, Food & Drug Administration (FDA), Immunotherapy, Regulatory/Compliance, Vascular, Wall Street Beat Tagged With: BioCardia

BioCardia files 2nd FDA IDE bid for CardiAMP chronic myocardial ischemia, refractory angina study

January 5, 2018 By Fink Densford

BioCardia

BioCardia (NSDQ:BCDA) said today it filed for a second FDA investigational device exemption to launch a trial of its CardiAMP cell therapy for treating chronic myocardial ischemia and refractory angina as it seeks a second indication. The San Carlos, Calif.-based company’s CardiAMP therapy uses autologous cells to treat chronic myocardial ischemia, and is designed to stimulate […]

Filed Under: Cardiovascular, Clinical Trials, Featured, Food & Drug Administration (FDA), Regenerative Medicine Tagged With: BioCardia

BioCardia treats 10-patient cohort in late-stage heart failure trial

July 26, 2017 By Sarah Faulkner

BioCardia

BioCardia (NSDQ:BCDA) said today that it finished treating a 10-patient cohort in its pivotal Phase III CardiAmp heart failure trial. The company reported that it expects a review of the 30-day outcomes for this cohort in the third quarter of this year. The CardiAmp pivotal trial, which launched in December, is slated to enroll up to […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Stem Cells, Wall Street Beat Tagged With: BioCardia

BioCardia, Johns Hopkins treats first patient with CardiAmp cell therapy in Phase III trial

February 28, 2017 By Sarah Faulkner

BioCardia

Johns Hopkins, the Maryland Stem Cell Research Fund and BioCardia (NSDQ:BCDA) said today that the 1st patient has been treated in a pivotal Phase III trial of the CardiAmp cell-based therapy for the treatment of ischemic heart failure. The investigational therapy was designed to deliver a dose of a patient’s own bone marrow cells directly […]

Filed Under: Cardiovascular, Clinical Trials, Featured, Regenerative Medicine, Wall Street Beat Tagged With: BioCardia, Johns Hopkins

BioCardia launches pivotal trial for CardiAmp heart failure treatment

December 30, 2016 By Sarah Faulkner

BioCardia (NSDQ:BCDA) initiated its CardiAmp pivotal trial this week to evaluate its cell therapy at 40 clinical sites across the U.S. The pivotal trial is a part of the company’s efforts for premarket approval, as regulated by the FDA’s Center for Biologics Evaluation and Research division. “We are honored to be working with the leading […]

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Stem Cells, Vascular Tagged With: BioCardia

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS